Latest news for Fernhill Beverage (OTC:FHBC) Stock

Fernhill Beverage Inc is a United States based beverage company. It is engaged in developing, creating and marketing beverage products. The company's flagship beverage product brand is called Roadkill. In addition, the entity is also focused on the development of other products aimed at the teen and pre-adult market to add to the product lines.

FERNHILL BEVERAGE INC by Fernhill Beverage, Inc.

Fernhill Beverage Inc

NASDAQ began listing options on <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42058823/blackrocks-spot-bitcoin-etf-to-open-for-options-trading-heres-why-it-could-be-a-big-deal-for-bitcoin">BlackRock&#8217;s iShares Bitcoin Trust</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) today, a move that is expected to revolutionize how institutional investors engage with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), providing them with a regulated and accessible avenue to hedge positions and generate yield.
What Happened: According to Eric Balchunas, Senior ETF Analyst at Bloomberg, options volume for IBIT exceeded several hundred million by mid-day, with most of them betting on rising Bitcoin prices.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">A few hundred million so far in options volume on <a href="https://twitter.com/search?q=%24IBIT&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$IBIT</a> (a ton for Day One).. here&#39;s a rank of the contracts by volume, it&#39;s almost all calls. Seems very bullish, esp the Dec20th C100, which is basically betting price of btc will double in the next month. <a href="https://t.co/R6HB7OMUla">pic.twitter.com/R6HB7OMUla</a>
&mdash; Eric Balchunas (@EricBalchunas) <a href="https://twitter.com/EricBalchunas/status/1858916477384225005?ref_src=twsrc%5Etfw">November 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The availability of options on IBIT brings a significant development to the U.S.-based Bitcoin ETF landscape, where BlackRock's IBIT stands out as the only ETF listed on NASDAQ. 
Options, as derivatives, allow investors to buy or sell IBIT shares at a predetermined price within a specified period, enabling both leveraged bets and effective hedging strategies.
On Nov. 18, Bitcoin spot ETFs recorded a net inflow of $255 million, with BlackRock&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) accounting for $89.3 million and Fidelity&#8216;s (CBOE: FBTC) contributing $59.9 million. 
In contrast, Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) spot ETFs faced a net outflow of $39 million.
The Options Clearing Corporation (OCC) on Monday <a href="https://www.theblock.co/post/327072/options-trading-on-spot-bitcoin-etfs-may-launch-this-week-as-occ-preparing-for-the-clearance">confirmed</a> its readiness to clear these options, completing the final regulatory step required for their launch.
IBIT, having gained earlier approval, is expected to lead the market by one to two days over competing ETFs. 
This early launch advantage underscores BlackRock&#8217;s strategic positioning in the crypto-linked financial products sector.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42059827/crypto-exchange-gemini-launches-services-in-france-following-regulatory-approval">Crypto Exchange Gemini Launches Services In France Following Regulatory Approval</a>
Why It Matters: According to QCP Capital, this development is likely to attract institutional investors who face restrictions in accessing native crypto options markets like Deribit.
"This could provide the foundation BTC needs for a move higher," QCP noted, highlighting the potential impact of options trading on Bitcoin's price dynamics.
The introduction of IBIT options also shifts the role of traditional Bitcoin exposure vehicles like MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>). 
Historically used as a proxy for Bitcoin exposure due to its substantial BTC holdings, MSTR options may see reduced reliance as traders transition to ETF-based options. 
Similarly, CME futures, a staple in institutional Bitcoin strategies, could experience a decline in usage. 
Options on IBIT offer a more cost-effective and flexible hedging mechanism, potentially compressing arbitrage spreads while opening avenues for sophisticated strategies.
As institutional interest grows, the Bitcoin derivatives market is expected to see enhanced liquidity, improved efficiency, and increased complexity. 
The derivatives market for traditional assets often grows to be 10-20 times the size of the underlying asset's market cap. 
If Bitcoin derivatives follow a similar trajectory, the listing of IBIT options could significantly expand the reach and functionality of Bitcoin-linked financial products.
Bitcoin's price remains in a tight consolidation just below its all-time high of $93,400, signaling a healthy pause in the market. 
Illia Otychenko, Lead Analyst at CEX.IO told Benzinga that this consolidation, paired with consistently higher lows, positions Bitcoin for a potential breakout above $93,400, which could mirror its December 2020 rally dynamics.
While 11 spot Bitcoin ETFs are currently on the U.S. market, IBIT's listing on NASDAQ uniquely qualifies it for options trading. 
The SEC's approval of these options, alongside rule changes for other ETFs on NYSE and Cboe, highlights the evolving regulatory landscape for Bitcoin financial products.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42049664/paul-tudor-jones-boosts-bitcoin-holdings-potentially-making-btc-his-largest-non-options-investment">Paul Tudor Jones Boosts Bitcoin Holdings, Potentially Making BTC His Largest Non-Options Investment</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$ETH

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

IBIT

MSTR

BlackRock Spot Bitcoin ETF Options On Nasdaq Rack Up 9-Figure Trading Volume In First Few Hours: 'Seems Very Bullish,' Says Analyst

On Tuesday, GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in adults with cholestatic pruritus (relentless itch) associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease.
GLISTEN <a target="_blank" href="https://www.gsk.com/en-gb/media/press-releases/linerixibat-shows-positive-phase-iii-results-in-cholestatic-pruritus/" rel="noreferrer noopener">met</a> its primary endpoint, with linerixibat improving itch, as demonstrated by a statistically significant reduction from baseline in monthly itch score over 24 weeks versus placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41986367/gsk-raises-prospects-for-withdrawn-blood-cancer-drug-blenrep-to-return-to-us-market-heres-why" rel="noreferrer noopener">GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market &#8211; Here&#8217;s Why</a>
The trial recruited PBC patients with moderate to severe itch who were receiving stable doses of guideline-suggested therapies for pruritus, were treatment naïve, or had been previously treated.
The preliminary safety results are generally consistent with those seen in prior studies of linerixibat. Further analysis of these data is ongoing.
Kaivan Khavandi, SVP &amp; Global Head, Respiratory/Immunology R&amp;D,&nbsp;GSK, said: &#8220;Linerixibat has the potential to be the first global therapy specifically developed to treat itch in PBC.&#8221;
People who have been diagnosed with PBC will reach 510,000 globally by 2030, and more than 240,000 people will experience relentless itch requiring treatment.
The full results of GLISTEN will be presented at a future scientific congress.
Investigational Linerixibat has been granted Orphan Drug Designation in the U.S. and EU.
In August this year, GSK <a target="_blank" href="https://www.nice.org.uk/guidance/awaiting-development/gid-ta11307" rel="noreferrer noopener">requested</a> a timeline adjustment, so the appraisal is expected to start in late September 2025. Submissions will be due around late November 2025.
This change allows the company more time to prepare a thorough and detailed submission for the National Institute for Health and Care Excellence (NICE).
Price Action: GSK stock is down 0.56% at $33.50 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42061321/vipshop-q3-earnings-revenue-beats-estimates-despite-order-decline-strong-margins-amid-soft-sales-reveals-q4-guidance-and-share-buybacks" target="_blank" rel="noreferrer noopener">Vipshop Beats Q3 Estimates Despite Sales Dip, Focuses On Long-Term Resilience</a></li>
</ul>

Biotech

Large Cap

Health Care

General

GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients

Stellantis Launches Third All-New, Multi-energy Platform:&nbsp; STLA Frame Offers Best-in-Class 690-Mile Electrified Range or 500-Mile BEV Range, Towing and Payload
<ul>
<li>Designed for full-size, body-on-frame trucks and SUVs, STLA Frame is versatile: supports internal combustion, hybrid, hydrogen, battery electric (BEV) and range-extender electric vehicle (REEV) technologies</li>
<li>The scalable STLA Frame is targeted to deliver best-in-class capabilities, including up to 690 mile/1,100 km of range with REEV and 500 mile/800km with BEV, 2,700-pound payload and 14,000-pound towing capacity</li>
<li>Dual electric drive modules (EDMs) deliver standard all-wheel drive capability with smooth, independent suspension</li>
<li>Engineered with high flexibility, STLA Frame features 400-volt and 800-volt EV architectures and offers DC fast charging up to 350 kW, adding 100 miles in just 10 minutes</li>
<li>Ram and Jeep&#xAE; brand vehicles are the first to use STLA Frame</li>
</ul>
AMSTERDAM, November 19, 2024 – Stellantis N.V. today unveiled the STLA Frame platform, a BEV-native, multi-energy platform engineered for full-size body-on-frame pickup trucks and SUVs – a critical segment in North America and select global markets.
Full-size truck and SUV owners demand uncompromised power and durability and prioritize capability, practicality and performance. STLA Frame platform is designed to deliver class-leading range of up to 690 miles/1,100 km with the REEV and 500 miles/800 km in BEV, a maximum towing capacity of 14,000 pounds (6,350 kg) and a payload rating of 2,700 pounds (1,224 kg). Additionally, the platform supports water fording up to 24 inches (610 mm), making it ready for challenging environments and diverse use cases.
Intended to underpin Stellantis full-size pickup trucks, light commercial vehicles and SUVs, STLA Frame vehicles will initially be offered with an innovative propulsion lineup, including a full BEV system and a range-extended electric vehicle (REEV) configuration. STLA Frame can also accommodate internal combustion, hybrid and hydrogen propulsion systems in the future.
The REEV system, which combines a battery, front and rear electric drive modules (EDMs), on-board generator and internal combustion engine, allows drivers to haul or tow heavy loads over extended distance without sacrificing range. With no direct mechanical path from the engine to the wheels, the generator powers the EDMs to propel the vehicle and recharges the battery as needed, ensuring extended range under load conditions, while benefitting from the torque of the electric engines that bring the vehicle's dynamics to new heights.

STLA

Stellantis Unveils The STLA Frame Platform, A BEV-Native, Multi-Energy Platform Engineered For Full-Size Body-On-Frame Pickup Trucks And SUVs, A Critical Segment In North America And Select Global Markets

Needham analyst Chris Pierce initiated coverage on Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) at a Buy <a target="_blank" href="https://www.benzinga.com/quote/joby/analyst-ratings" rel="noreferrer noopener">rating with a price target of $8</a>.
The analyst says the company is well-positioned to capture early air taxi market share, supported by its partnership with Uber following the 2020 acquisition of Uber Elevate.
JOBY&#8217;s focus on software, particularly the ElevateOS platform, is encouraging as it lays the foundation for their future air taxi network, adds the analyst.
Pierce says that he is optimistic about <a target="_blank" href="https://www.benzinga.com//node/41551820" rel="noreferrer noopener">FAA air taxi regulation</a> and see JOBY gaining market share compared to existing transportation options.
In particular, the FAA&#8217;s Innovate 2028 plan underscores the long-term importance of the air taxi industry in the U.S., setting a foundation for domestic competitiveness.
JOBY&#8217;s expectation to operate passenger flights in the UAE by late 2025 subtly pressures the FAA to align with their timeline, reducing the likelihood of significant delays in the U.S. regulatory approval process, which is currently anticipated for 2026, adds the analyst.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/41754469" rel="noreferrer noopener">Air Mobility Stocks Prepare For Takeoff: Will Joby, Archer, Blade Soar Above Certification, Cash Challenges?</a>
The analyst writes that he sees a $3 billion early-stage global air taxi revenue opportunity, driven by conservative eVTOL penetration of airport and metro transit trips, based on passenger data from the world&#8217;s busiest airports and NYC metro area train ridership.
The model assumes just 25 basis points of industry penetration in 2029, with supply constraints easing and rider interest growing at accelerated rates due to the time savings offered by air taxis at comparable per-mile price points to current rideshare options, adds the analyst.
Pierce writes that JOBY&#8217;s clean-sheet manufacturing and vertically integrated engineering approach are expected to drive lower aircraft COGS, enabling quicker payback periods and solidifying its leadership position in the air taxi industry.
The analyst anticipates multiple winners in the sector, with strategic crossovers and competition as go-to-market strategies evolve and end markets develop.
Investors can gain exposure to the stock via&nbsp;WisdomTree Trust WisdomTree Battery Value Chain and Innovation Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/WBAT#BATS">WBAT</a>) and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>).
Price Action: JOBY shares are up 7.22% at $6.015 at the last check Tuesday.
Image via Joby Aviation
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41146425" target="_blank" rel="noreferrer noopener">Toyota Doubles Down On Joby Aviation: $500M Investment Powers US Electric Air Taxi Certification, Production</a></li>
</ul>

Analyst Color

Equities

Mid Cap

Price Target

Initiation

Analyst Ratings

Trading Ideas

ARKX

JOBY

WBAT

Joby Aviation Positioned For Air Taxi Leadership, Thanks To FAA Backing And Uber Partnership: Analyst

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) advocate Anthony Pompliano calls for the new Donald Trump administration to buy $250 billion in the leading cryptocurrency on day one of the new regime, as reports grow for a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41938972/donald-trump-to-establish-a-national-bitcoin-reserve-a-30-chance-polymarket-traders-speculate">Bitcoin Strategic Reserve.</a>
What Happened: Pompliano was asked how Trump can make a difference for the cryptocurrency sector during a discussion at the 2024<a href="https://www.benzinga.com/digital-assets"> Benzinga Future of Digital Assets </a>event on Nov. 19.
The investor and entrepreneur didn't hold back with commentary on how positive the Trump administration could be for the cryptocurrency and with his suggestion to make an initial mark felt worldwide.
"It's not about individual policy, it's about the signal that we're changing regimes. The new regime is pro-Bitcoin," Pompliano said.
Pompliano said he has an upcoming piece coming out that will call on the U.S. to buy $250 billion in Bitcoin on day one of the new administration. The investor said in order to make the purchase, the country could print the money.
With the purchase, and around 200,000 Bitcoin already owned, the U.S. would become the largest holder in the world.
Pompliano said the $250 billion amount may sound like a lot, but it's a "rounding error" compared to the hundreds of billions of debt added to the national debt.
"Protect our future, it's such a no brainer."
Advocating against the Bitcoin strategic reserve could represent being against the growth of the U.S., Pompliano added.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41403206/bitcoin-is-the-simplest-story-in-finance-will-climb-regardless-of-election-winner-says-ant">Bitcoin Is &#8216;The Simplest Story In Finance,&#8217; Will Climb Regardless Of Election Winner, Says Anthony Pompliano</a>
Why It's Important: The comments from Pompliano come as Bitcoin has soared in value since Donald Trump won the 2024 presidential election, hitting multiple new all-time highs in November 2024.
Pompliano said the move by the U.S. would show the country's support for Bitcoin and could elevate the value and make the country's investment pay off.
BTC Price Action: Bitcoin trades at $92,517.23 at the time of writing, up 1% over the last 24 hours and up 6% over the last week. Bitcoin hit an all-time high of $93,434.26 on Nov. 13.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41916359/bitcoin-is-the-decentralized-king-says-anthony-pompliano-whose-100000-price-prediction-is-close-to-coming-true">Bitcoin Is The &#8216;Decentralized King,&#8217; Says Anthony Pompliano, Whose $100,000 Price Prediction Is Close To Coming True</a></li>
</ul>
Photos: Shutterstock

Government

Politics

Events

Exclusives

EXCLUSIVE: Anthony Pompliano Calls For US To Buy $250B Bitcoin On Day 1 Of Trump Administration: 'Protect Our Future, It's Such A No Brainer'

On Tuesday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed topline results from the pivotal Phase 3 MK-3475A-D77 trial evaluating the noninferiority of subcutaneous administration of pembrolizumab together with berahyaluronidase alfa, administered with chemotherapy versus intravenous (IV) Keytruda administered with chemotherapy for the first-line treatment of adult patients with metastatic non-small <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42058324/merck-announces-phase-3-trial-of-subcutaneous-pembrolizumab-with-berahyaluronidase-alfa-met-primar" rel="noreferrer noopener">cell lung cancer (NSCLC)</a>.
Pembrolizumab is available for intravenous use as Keytruda,
Berahyaluronidase alfa is a hyaluronidase variant developed and manufactured by Alteogen Inc.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42013119/whats-going-on-with-large-european-and-us-vaccine-makers" rel="noreferrer noopener">European And US Vaccine Stocks Are Under Pressure &#8211; Here&#8217;s WHy</a>
The Phase 3 trial met its dual primary pharmacokinetic (PK) endpoints.
Specifically, subcutaneous pembrolizumab administered every six weeks with chemotherapy demonstrated noninferiority of Area Under the Curve (AUC) exposure of pembrolizumab during the first dosing cycle, and trough concentration (Ctrough) of pembrolizumab measured at steady state, compared to IV Keytruda administered every six weeks in combination with chemotherapy.
Additionally, secondary efficacy and safety endpoints were generally consistent for subcutaneous pembrolizumab administered with chemotherapy compared with IV Keytruda administered with chemotherapy.
These results and those from ongoing analyses will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.
In addition to the Phase 3 MK-3475A-D77 trial, Merck&#8217;s subcutaneous pembrolizumab clinical development program includes the Phase 3 MK-3475A-F84 trial evaluating subcutaneous pembrolizumab administered alone compared to IV Keytruda for the first-line treatment of patients with metastatic NSCLC whose tumors have high PD-L1 expression, as well as the Phase 2 MK-3475A-F65 trial evaluating subcutaneous pembrolizumab administered alone in relapsed or refractory classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Merck is also conducting a Phase 2 patient preference study, MK-3475A-F11, evaluating participant-reported preference for subcutaneous pembrolizumab compared to IV Keytruda.
Price Action: MRK stock is down 0.56% at $96.03 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42062234/whats-going-on-with-nio-stock-following-strong-q3-results-from-top-peer-xpeng" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With NIO Stock Following Strong Q3 Results From Top Peer XPeng?</a></li>
</ul>
Photo Courtesy of Merck

Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients

Think $3 million is a solid retirement fund? <a href="https://www.benzinga.com/personal-finance/24/11/41991146/suze-orman-says-this-investment-can-make-your-kids-rich-by-retirement-you-have-a-golden-opportunity-to-launch-them-to-their-first-million">Suze Orman has a reality check</a> for you.&nbsp;
Speaking on the "Afford Anything" podcast, she explained why even this seemingly hefty amount might leave you struggling in retirement – especially if life throws a few curveballs your way.&nbsp;
Don't Miss:
<ul>
<li>The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"> Here are three ways to join the club.</a></li>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li><a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a></li>
</ul>
Orman was asked whether $3 million, paired with a conservative 3% withdrawal rate, could fund a secure early retirement. Her response? A flat-out no. She didn't even hesitate to poke holes in the idea, calling $3 million "far from enough" for the unexpected costs life can throw at you.
The host, Paula Pant, asked Orman, "What would be a safe amount at which a person can say, ‘All right, at this point, given the size of my portfolio, I&#8217;m comfortable enough that if I did get hit by a bus, I would be fine.'?"
Orman answered, "It would have to be in the millions." Pant, wanting a clearer answer, pressed further: "How many million?" That's when Orman started doing the math – it wasn't pretty.
"It depends where you live, what your expenses are," Orman said. "Do you own your home outright? So, what are your expenses? But just think about it logically."
And then she did exactly that: <a href="https://www.benzinga.com/personal-finance/24/09/40950245/suze-orman-says-missing-this-one-crucial-monthly-payment-could-cost-you-big-heres-the-first-bill">broke it down, line by line</a>.
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a>
"Let's say you need help. Remember, I took care of my mother and it cost me, like I said, $30,000 a month. $30,000 a month," Orman emphasized. "So, you're talking about, very possibly, for full-time help and everything – because good luck getting insurance and things to pay for it now – you're talking about maybe $300,000, $400,000 a year."
If that wasn't sobering enough, she added: "Now you have other expenses – food and everything. Let's just say you need another $100,000 a year to live. So now you're at $350,000 a year after taxes."
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
To generate $350,000 annually after taxes without touching your principal, Orman said you'd need a portfolio yielding at least 5%. That means a whopping $10 million in assets, if not more.
"Even if you have $1 million right now and you're getting a 4% yield, that's $40,000," she pointed out. "So you need at least $5 million, $6 million. And that's before tax. So you need a 5% after-tax yield in municipal bonds to get you $300,000."
Orman's conclusion? "You might need $10 million, just so if you're making 5% on that money after tax, you'll be fine without touching your principal."
The famed financial guru's advice wasn't about scaring people but about being brutally realistic. She reminded listeners that unexpected costs, like long-term care, health crises or inflation, could quickly wipe out even a seemingly comfortable nest egg.
See Also: <a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a>
Now, although Orman insists you'll be spending far more than you realize in retirement, the average retiree spends around $4,345 per month or about $52,141 annually, on living expenses, according to data. Her basis is a breakdown of her experience and the expenses she endured, which may not necessarily be what the "average" retiree encounters.&nbsp;
While her comments sparked debate, particularly among those in the <a href="https://www.benzinga.com/personal-finance/24/11/41781968/suze-orman-says-if-youre-rich-like-her-then-you-can-retire-early-but-if-you-only-have-2-million-">FIRE (Financial Independence, Retire Early) community</a>, Orman's warning boiled down to this: Plan for the worst because running out of money in retirement isn't something you want to gamble with.
If you're <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">banking on early retirement</a>, her advice is clear – do the math and then do it again. As Orman sees it, underestimating your needs now could leave you with fewer choices later.
Read Next:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>

Personal Finance

Suze Orman Warns $3 Million Isn't Enough For Retirement, Even At A Mere 3% Withdrawal Rate – She Says You Need $10 Million Or More

Wendy's's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NYSE">WEN</a>) short percent of float has fallen 12.93% since its last report. The company recently reported that it has 10.83 million shares sold short, which is 7.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.4 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Wendy's Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732040123_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Wendy's has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Wendy's's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Wendy's's peer group average for short interest as a percentage of float is 9.99%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Wendy's?

Textron's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) short percent of float has risen 6.67% since its last report. The company recently reported that it has 3.89 million shares sold short, which is 2.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Textron Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732040118_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Textron has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Textron's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Textron's peer group average for short interest as a percentage of float is 2.99%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Textron?

Macro Economic Events

Economics

Federal Reserve

Kansas City Fed's Schmid Says It Remains To Be Seen How Far Interest Rates Might Fall; Rate Cuts Are An Acknowledgment Of Fed's Confidence Inflation Is On A Path To 2% Target; Large Fiscal Deficits Will Not Cause Inflation Because The Fed Will Prevent It, Though That Could Mean Higher Interest Rates

Permian Resources's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>) short percent of float has fallen 6.4% since its last report. The company recently reported that it has 31.70 million shares sold short, which is 4.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.98 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Permian Resources Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732040113_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Permian Resources has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Permian Resources's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Permian Resources's peer group average for short interest as a percentage of float is 6.49%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Permian Resources's Recent Short Interest

Complete cloud repository data security enables customers to securely leverage the cloud for business agility
MICROSOFT IGNITE -<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.rubrik.com%2F&amp;esheet=54154601&amp;newsitemid=20241119672620&amp;lan=en-US&amp;anchor=Rubrik%2C+Inc.&amp;index=1&amp;md5=917b77bbd34636b9883d61268426f5a7">Rubrik, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>), the Zero Trust Data Security&#x2122; Company, today announces a new cyber resilience solution for <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fazure.microsoft.com%2Fen-us%2Fproducts%2Fstorage%2Fblobs&amp;esheet=54154601&amp;newsitemid=20241119672620&amp;lan=en-US&amp;anchor=Microsoft+Azure+Blob+Storage&amp;index=2&amp;md5=5965cd9378e23b0764d11ab358dea0fd">Microsoft Azure Blob Storage</a>. As organizations become increasingly dependent on the cloud, there is an inherent risk for security blind spots and vulnerable sensitive data. Rubrik brings cyber posture and cyber recovery to provide Microsoft Azure Blob Storage customers further visibility into their cloud data, enabling business agility and resilience.
Microsoft Azure Blob Storage provides secure object storage for cloud-native workloads, archives, data lakes, high-performance computing, and machine learning. Optimized for storing massive amounts of unstructured data, organizations across all industries use Microsoft Azure Blob Storage as a critical repository for sensitive business information, personal data, compliance records, and data powering artificial intelligence (AI) training models.

MSFT

RBRK

Rubrik Delivers Cyber Resilience Solution For Microsoft Azure Blob Storage; Complete Cloud Repository Data Security Enables Customers To Securely Leverage The Cloud For Business Agility

<a href="https://www.bloomberg.com/news/articles/2024-11-19/airbus-ceo-says-year-end-delivery-goal-is-a-tough-journey">https://www.bloomberg.com/news/articles/2024-11-19/airbus-ceo-says-year-end-delivery-goal-is-a-tough-journey</a>
Airbus SE Chief Executive Officer Guillaume Faury said that hitting a goal of 770 aircraft deliveries this year will be a sprint over the final weeks as the planemaker pushes to reach an already reduced target.
"I've seen too many years where we had the last minute," Faury said in an interview in Brussels, where he was attending a conference. "It's a tough journey and we're a bit late compared to what we were expecting. 770 is still our reference and we're working against that reference, and hopefully it's going to work."

European Aeronautic Defence And Space Unsponsored

EADSY

"Airbus CEO Says Year-End Delivery Goal Is 'A Tough Journey'" - Bloomberg News

On Monday,&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;announced Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a genetically inherited risk <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42047055/lillys-muvalaplin-lowered-lipoprotein-a-levels-in-adults-with-high-risk-for-cardiovascular-events-" rel="noreferrer noopener">factor for heart disease</a>.
In the U.S., about 20% of people, or approximately 63 million individuals, have high levels of Lp(a).
Elevated Lp(a) levels can double or even triple the risk of a heart attack and are associated with other cardiovascular issues.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/42039286/eli-lillys-zepbound-mounjaro-shows-cardiovascular-benefits-in-patients-with-obesity-related-heart-failure" rel="noreferrer noopener">Eli Lilly&#8217;s Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure</a>
The study demonstrated that muvalaplin significantly reduced elevated Lp(a) levels in adults, meeting its primary endpoint.
At the 12-week primary endpoint, muvalaplin (10 mg, 60 mg, and 240 mg) significantly reduced Lp(a) levels compared to placebo.
The placebo-adjusted reductions were up to 85.8% using an intact Lp(a) assay and up to 70.0% using an apo(a) assay.
<ul>
<li>Specifically, the reductions were 47.6% (10 mg), 81.7% (60 mg) and 85.8% (240 mg) with the intact Lp(a) assay, and 40.4% (10 mg), 70.0% (60 mg) and 68.9% (240 mg) with the apo(a) assay.</li>
</ul>
Muvalaplin also met secondary endpoints for all three tested doses (10 mg, 60 mg, and 240 mg).
<ul>
<li>The three tested doses achieved statistical significance for Lp(a) thresholds, and the 60 mg and 240 mg doses also achieved statistical significance for apoB reductions.</li>
</ul>
These data also demonstrated:
<ul>
<li>Using the intact Lp(a) assay, the percentage of participants achieving normal Lp(a) levels of less than 125 nmol/L at week 12 was 64.2% (10 mg), 95.9% (60 mg), and 96.7% (240 mg), compared to 6.0% in the placebo group.</li>
<li>Using the apo(a) assay, 38.9% (10 mg), 81.9% (60 mg), and 77.4% (240 mg) of participants achieved an Lp (a) level of less than 125 nmol/L, compared to 3.6% in the placebo group.</li>
<li>ApoB levels were reduced at all doses, with placebo-adjusted reductions of 8.9% (10 mg), 13.1% (60 mg) and 16.1% (240 mg).</li>
</ul>
Adverse events were similar in both the muvalaplin and placebo groups.
Price Action: LLY stock is down 0.44% at $723.97&nbsp;at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42060801/walmart-tops-q3-estimates-ecommerce-growth-shines-with-27-lifts-full-year-forecast" target="_blank" rel="noreferrer noopener">Walmart Q3 Earnings: Revenue Beat, eCommerce Growth Shines, Issues Bullish Outlook For FY25</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%

<a href="https://www.bloomberg.com/news/articles/2024-11-19/microsoft-signs-ai-learning-deal-with-news-corp-s-harpercollins">https://www.bloomberg.com/news/articles/2024-11-19/microsoft-signs-ai-learning-deal-with-news-corp-s-harpercollins</a>
&nbsp;
<a href="https://www.bloomberg.com/quote/MSFT:US">Microsoft Corp.</a> reached a deal with <a href="https://www.bloomberg.com/quote/NWSA:US">News Corp.</a>'s HarperCollins that will allow the software company to use nonfiction titles from the book publisher to train its artificial intelligence models, according to a person familiar with the matter.
Microsoft wants the HarperCollins books for a model that it hasn't yet announced, according to the person, who asked not to be identified discussing plans that aren't public. The company isn't planning to use the content to generate new books without human authors, the person said. Microsoft declined to comment.

NWSA

'Microsoft Signs AI-Learning Deal With News Corp's HarperCollins; Nonfiction Books Will Be Used For Training AI Models; AI Companies And Publishers Have Butted Heads In Lawsuits' - Bloomberg News

WIIM

Comfort Systems USA shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised its price target from $396 to $525.

SOFI

SoFi Technologies shares are trading higher after Mizuho maintained an Outperform rating on the stock and raised its price target from $14 to $16.

Red Hat Expands AI Innovation With RHEL AI on Microsoft Azure, Enabling Seamless Generative AI Deployment Across Hybrid Cloud Environments

Tryptamine Therapeutics Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TYPTF#OTC">TYPTF</a>) has <a href="https://www.proactiveinvestors.com.au/companies/news/1060916/tryptamine-therapeutics-will-advance-to-trp-8803-psilocin-phase-2-clinical-trials-1060916.html">announced</a> that its lead asset, TRP-8803, a <a href="https://www.benzinga.com/topic/psilocin">psilocin-based</a> IV infusion, will progress to <a href="https://www.benzinga.com/topic/psychedelics-research">Phase 2 clinical</a> trials following a successful Phase 1b study. <a href="https://www.benzinga.com/markets/cannabis/22/10/29142049/this-psychedelics-company-is-patenting-its-psilocin-and-psilocybin-delivery-route">TRP-8803</a> demonstrated significant advantages over oral <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a>, including rapid onset, precise control of the psychedelic state and the ability to halt treatment if adverse events occur, enhancing patient safety. 
<h3 class="wp-block-heading">Phase 1b Achievements</h3>
TRP-8803 was well-tolerated across all tested doses—low, mid and high—demonstrating its safety profile. The study identified optimal doses and infusion rates that maintained psilocin blood levels within the therapeutic range. Additionally, TRP-8803 achieved steady and controlled blood levels, outperforming oral psilocybin formulations in terms of consistency.
Participants experienced a rapid onset of the psychedelic state, much faster than the typical one- to two-hour delay with oral psilocybin. "To have achieved these positive results from our Phase 1b for TRP-8803 study so quickly has exceeded all expectations," said Tryptamine CEO Jason Carroll.
<h3 class="wp-block-heading">Path To Phase 2</h3>
Armed with a robust proprietary dataset, Tryptamine is preparing to advance TRP-8803 to active patient studies. Phase 2 trials will target specific therapeutic indications, with planning already underway. Carroll highlighted the importance of these findings, stating, &#8220;Tryp has now established the strong foundations essential to advance our world-first trials for IV-infused psilocin to the highest standards of safety, quality and integrity.&#8221;
<h3 class="wp-block-heading">TRP-8803: A Transformative Approach</h3>
TRP-8803 offers multiple advantages over traditional oral psilocybin. It provides faster onset, precise control over treatment duration and reversibility, enabling clinicians to halt therapy immediately if necessary. These features make the treatment safer and more commercially viable while reducing the overall duration of therapy. By promoting neuroplasticity, TRP-8803 aims to drive adaptive structural and functional changes in the brain, solidifying Tryptamine's position at the forefront of psychedelic medical innovation.
Cove imgage made with AI

Comments

Fernhill Beverage

News

Latest news for Fernhill Beverage (OTC:FHBC) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga